12 trends tracked about this subject — the full history, oldest to newest below.
AstraZeneca ends a Phase 3 lung cancer drug trial for volrustomig after a formal review determines success is unlikely.
Analysts express perplexity as reports indicate active merger talks between Bristol-Myers Squibb and AstraZeneca.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AstraZeneca investors are resisting proposed acquisition talks with Bristol Myers valued at $400 billion.
AstraZeneca shares have declined following reports of potential $400 billion merger talks with Bristol Myers Squibb.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
GSK is launching a $2.5 billion cost-saving initiative to accelerate its late-stage drug pipeline and relocate its research headquarters.
AstraZeneca’s earnings beat lifts its stock as oncology sales buoy growth and offset a rare drug miss.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AstraZeneca shares dropped six percent following a heart drug trial setback that simultaneously boosted rival stocks.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.